

U.S.S.N. 09/445,865

Filed: February 11, 2000

AMENDMENT AND RESPONSE TO OFFICE ACTION

In the Claims

1-28 canceled.

29. (currently amended) A method of treating a human patient with a target cell to be destroyed wherein the target cell expresses NQO2 the method comprising administering to the patient a prodrug which is converted to a cytotoxic drug by the action of NQO2 and an analogue of nicotinamide riboside (reduced) (NRH) ~~having formula I:~~ which can pass reducing equivalents to NQO2, wherein the prodrug is CB 1954, and wherein ~~R1 is the analogue of nicotinamide riboside (reduced) (NRH) is 1-(carboxamidomethyl) dihydronicotinamide selected from the group consisting of: substituted alkyl, including substitution by CONH2, OH, halogen, CN and COOH; alkyl; aryl; substituted aryl; CONR^aR^b, where R^a and R^b are independently H, alkyl, or substituted alkyl, and R² and R³ are independently H, alkyl, or substituted alkyl and R⁴ is any of H, alkyl, substituted alkyl, halogen, CN, COOH, CONH2, or OH.~~

30. canceled.

31. (previously presented) The method of claim 29 wherein the analogue of NRH is able to permeate the target cell membrane.

32. (previously presented) The method of claim 29 wherein the target cell is a tumour.

33. (previously presented) The method of claim 29, the method further comprising determining, before administering the prodrug and analogue of NRH, whether the target cell to be treated expresses NQO2.

34-39 canceled.

NOV. 25. 2003 10:22AM

HOLLAND & KNIGHT

NO. 3599 P. 6

U.S.S.N. 09/445,865

Filed: February 11, 2000

AMENDMENT AND RESPONSE TO OFFICE ACTION

40. (original) The method of claim 29 wherein the patient has cancer.

41-44 canceled.